Martin Braddock, Frsb, Fras Email & Phone Number

East Midlands, England, United Kingdom

Who I am and what I have:- Experienced project leader with a proven track record of leading activities at all phases of early stage science, drug discovery and development up to 10s-100s $M projects in global roles, manager and scientist with an International scientific reputation. - Broad expertise across multiple therapeutic areas including respiratory, inflammatory and autoimmune disease, cardiovascular disease and tissue repair and regeneration. - Drug discovery and development experience from concept to target ID through to phase I-III clinical development, leading teams to deliver regulatory submissions and product approvals in multiple countries; brand maintenance activities including license to operate.What I can bring: - Honest, down-to-earth and independent opinion gained from 40+ years’ experience. - Guidance for biotechs, universities, research organisations and large biopharma to progress drug candidates into and through clinical development to help build the ‘Science Behind their Business’. This includes building basic pharmacology studies for target validation, delivering target product profiles, clinical development plans. - Advice on future product potential and positioning within the current and to-be competitive environments. What I am looking for: - Open discussions with potential clients who recognise their knowledge gaps. - Consulting assignments from ad hoc project work through to portfolio potential product assessment. - Therapeutic area agnostic assignments driven by high quality science and fast decision making.

Cambridge, England, United Kingdom

Leadership of a Global Product Team which delivers regulatory submissions/approvals and licence to operate maintenance activities for 9 products/brands supporting ~ $3Bn sales revenue in 2023.

Cambridge, England, United Kingdom

Team lead for our SARS-Cov-2 monoclonal antibody project

Cambridge, United Kingdom

Leadership of a Global Product Team for established respiratory brands and nebulised products for both China and International markets. Pioneered two innovative technologies to maintain medicine quality, protecting > $100M sales, supported by negotiation and agreement with multiple internal and external multiple stakeholders.

Rome, Latium, Italy

Granta Park, Cambridge Uk

Project management of Tezepelumab phase III development in severe asthma and life cycle management. Co-development project with Amgen.

Granta Park, Cambridge Uk

Project management of Tralokinumab phase III development in severe asthma and in leading and supporting multiple activities in preparation for regulatory submissions. Alliance Manager (until May 2017) for transition of Tralokinumab to LEO Pharmaceuticals for development in atopic dermatitis.

Global Medicines Development, Alderley Park, Macclesfield

Responsible for building and strengthen the science throughout the phase III clinical programme, aligned to the target product profile to support both the regulatory submission and the developing brand within the portfolio of late stage development candidates.Led scientific input for >10 licensing opportunities in respiratory/vascular disease/tissue repair.

Global Medicines Development, Alderley Park, Macclesfiled

Responsible for delivery of scientific support, through rigorous construction of non-clinical, translational and clinical science build for multiple late stage phase IIb and phase III clinical development projects in Inflammation, Neuroscience and Respiratory Global Medicines Development in AstraZeneca and company subsiduaries.

Charnwood R&D, Loughborough

Role includes contributing to the development of scientists in R&D Charnwood, dissemination of AstraZeneca R&D science activities to external groups and bodies involved in science education and chair of the Science Leadership Team comprising scientists from chemistry, bioscience and DMPK from both Lund and Charnwood R&D sites.

Global Medicines Development, Alderley Park, Macclesfield

Fostamatinib is a SYK inhibitor licensed by AstraZeneca from Rigel Pharmaceuticals for clinical development in rheumatoid arthritis (RA). The drug has now completed phase III clinical trials. As science lead, I had responsibility for ensuring that evolving science would support regulatory submission. In addition I developed the science plan to build the brand with a large number of external collaborators through both CROs and academic institutes for LCM including ITP for which the drug was approved at Rigel on 17th April 2018 and is now marketed as Tavalisse.

Charnwood R&D, Loughborough

Leader of the Global Biology Network (GBN) across all AstraZeneca research sites. The GBN is reponsible for harmonisation of processes involving bioscience in all aspects of drug discovery from pre-competitive data sharing, target identification and validation through to asset exploitation, candidate drug re-positioning, exploiting value in co-morbid indications and new technology investments.

Charnwood R&D, Loughborough

Head of Discovery Bioscience with line mangement responsibility for 82 people specialising in lead optimisation drug discovery and translational science for both small molecule and biological projects. Therapeutic areas covered are respiratory (asthma, COPD), autoimmune disease (RA) and OA with a variety of targets including chemokines, cytokines and their cognate receptors, transporters, ion channels and kinases. While managing a budget of $6M, my department supported upto 22 compounds in early and mid-stage clinical development with product support and translational science activities.

Charnwood R&D, Loughborough

Lead optimisation project leader for a P2X7 receptor antagonist drug discovery project delivering three candidate drugs into clinical development for inflammatory and respiratory disease. Most advanced; AZD9056 reached phase IIb clinical development in rheumatoid arthritis.

Charnwood R&D, Loughborough

Line management responsiility for 18 staff working on lead optimisation drug discovery projects in autoimmune disease and respiratory.

Charnwood R&D, Loughborough

Chair of a cross-functional global discipline team setting strategic direction for the inflammation research area for projects in discovery and early development.

Medicines Research Centre, Stevenage

Head of Disease Cell Biology managing pre-clinical biology supporting multiple therapeutic areas (CNS - Alzheimer's; Respiratory - Asthma, COPD; Autoimmune disease - Rheumatology; Cardiovascular; Vascular Disease Prevention).

Medicines Research Centre, Stevenage

Responsible for discovery and validation of gene therapeutic approaches for promoting tissue repair in skin and bone and for skin anti-fibrotics.

Medicines Research Centre, Stevenage

JSC member for a functional genomics strategic intitiative with Nemapharm pharmaceuticals

Medicines Research Centre, Stevenage

Team Leader in Vascular Diseases Unit responsible for basic research in vascular biology, application of gene therapy to atherosclerosis and understanding and exploitation of fluid shear stress on gene expression in human vasculature.

Retrovirus Molecular Biology Group, Biochemistry Department University Of Oxford

Research grant holder supporting basic research in HIV biology, specialising in: determination of mechanism of action studies for leading anti-viral compounds at the level of gene expression, transcriptional and translational control of HIV open reading frames, masked message control of gene expression and mRNA sub-cellular localisation of intronic designed transcription units.

Retrovirus Molecular Biology Group, Biochemistry Department University Of Oxford

Post-doc in the lab of Susan and Alan Kingsman working on bovine papilloma virus and HIV molecular biology: transcriptional and translational control of E2, tat and rev open reading frames.

Oxford, England, United Kingdom

Academic tutor for final year BPhil biochemistry students for modules and dissertations in molecular virology.

Medical Sciences Institute, University Of Dundee

Post-doc in the lab of Grahame Hardie and Philip Cohen; MRC Protein Phosphorylation Group, Medical Sciences Institute working on the molecular cloning of mammalian fatty acid synthetase.

Ph.D, Radiation Biology

Effects of high LET radiation on DNA double strand breaks with size of DNA and pulse radiolysis analysis of hydroxyl free radicals adducts.

B.Sc., Biochemistry